<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="100000"><TitleDisplay>Stereotactic Body Radiation Therapy in Treating Patients With Low and Low-Intermediate-Risk Prostate Cancer</TitleDisplay><TitleOfficial>Study of Four-Fraction Split-Course Stereotactic Ablative Radiation Therapy of the Treatment of Patients With Low and Low-Intermediate Risk Adenocarcinoma of the Prostate</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MCC-14712</Identifier><Identifier type="NCT">NCT01737151</Identifier><Identifier type="Secondary Organisational">NCI-2012-02545</Identifier></Identifiers><Indications><Indication id="276">Prostate tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>stereotactic body radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20696" type="Company"><TargetEntity id="5000493178" type="organizationId">Virginia Commonwealth University Foundation</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="20696">Virginia Commonwealth University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>19</PatientCountEnrollment><DateStart>2013-03-08T00:00:00Z</DateStart><DateEnd type="estimated">2019-05-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-02T12:24:29Z</DateChangeLast><DateAdded>2012-11-30T09:52:48Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Massey Cancer Center</Affiliation><Name>Timothy J Harris, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have low or low-intermediate risk adenocarcinoma of the prostate as
             defined by:&lt;ul&gt;&lt;li&gt;Low-risk diseas- histopathology score (Gleason sum)&amp;lt;/= 6, and T-stage (per current American Joint
                  Committee on Cancer [AJCC] staging criteria): T1c to T2a, and prostate-specific
                  antigen (PSA) &amp;lt; 10&lt;/li&gt;&lt;li&gt;Intermediate-risk disease as either:&lt;ul&gt;&lt;li&gt;Histopathology score (Gleason sum)&amp;lt;/= 6, and T-stage (per current American Joint
                  Committee on Cancer [AJCC] staging criteria): T1c to T2a, and prostate-specific
                  antigen (PSA) &gt;  10 or &amp;lt; 20&lt;/li&gt;&lt;li&gt;Histopathology score (Gleason sum) 7 with&amp;lt;/=  50% of any cores positive, T-stage (per current AJCC staging criteria): T1c to T2a, and PSA &amp;lt; 10&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Charlson index of comorbidity score&amp;lt;/= 4
&lt;/li&gt;&lt;li&gt;Ability to understand and the willingness to sign a written informed consent document&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with history of inflammatory bowel disease, or who require steroid or
             cytotoxic therapy for collagen vascular disease&lt;/li&gt;&lt;li&gt;Patients with a history of cancer other than skin cancer within five years of the
             initiation of protocol treatment&lt;/li&gt;&lt;li&gt;Patients with a history of pelvic irradiation for any reason&lt;/li&gt;&lt;li&gt;Life expectancy&amp;lt; 10 years &lt;/li&gt;&lt;li&gt;Prior treatment with an anti-androgen, luteinizing
             hormone-releasing hormone (LHRH) agonist, or a combination of the two&lt;/li&gt;&lt;li&gt;Prior radiation therapy, brachytherapy, or cryotherapy&lt;/li&gt;&lt;li&gt;Prior surgical procedure involving peri-rectal and peri-prostatic area&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Late toxicity &gt;/= grade 2 as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria: will be tested using a continuity corrected chi-square test</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Biochemical failure as defined by the phoenix definition</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Protocol completion rate: the portion of patients completing the planned protocol with no unacceptable protocol violations is anticipated to be greater than 90%. A completion rate of 70% is deemed unacceptably low</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Patient-reported outcomes: International Index of Erectile Function (IIEF) and Expanded Prostate Cancer Index Composite urinary Assessment (EPIC) urinary and bowel assessments will be used to collect patient-reported outcomes. IIEF is a widely used instrument for the evaluation of male sexual function. It is has been recommended as tool for clinical trials of erectile dysfunction and for diagnostic evaluation of erectile dysfunction severity. 15 questions 1=very low (worst) to 5=very high (best). The EPIC urinary and bowel assessments are comprehensive instruments designed to evaluate urinary and bowel symptoms, thereby providing a unique tool for assessment of quality of life issues important in prostate cancer management. 9 questions 0=no problem to 5=big problem</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Acute toxicity greater than or equal to grade 2 as defined by the CTCAE version 4 criteria</Description><Timeframe>Up to 90 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized clinical trial is to study stereotactic body radiation therapy (SBRT) in treating
      patients with low- and low-intermediate-risk prostate cancer. The study hypothesis is  that stereotactic body radiation
      therapy may be able to send X-rays directly to the tumor and cause less damage to normal
      tissue.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Primary objectives:&lt;br/&gt;To evaluate, in terms of late toxicity, the safety of stereotactic radiation therapy using the proposed fractionation schedule.&lt;/para&gt;&lt;para&gt;Secondary objectives:&lt;br/&gt;To evaluate, in terms of acute toxicity, the safety of stereotactic radiation therapy using the proposed fractionation schedule.&lt;br/&gt;To determine stereotactic treatment efficacy through biochemical failure (Phoenix criteria).&lt;br/&gt;To determine the protocol completion rate.&lt;br/&gt;To describe patient-reported outcomes using International Index of Erectile Function (IIEF) and EPIC Urinary and Bowel Assessment questionnaires.&lt;/para&gt;&lt;para&gt;Outline: &lt;br/&gt;Patients will be  randomized to one of two treatment arms.&lt;br/&gt;Arm A (standard SBRT): patients will undergo standard daily fractions of SBRT over 7 to 8.5 weeks.&lt;br/&gt;Arm B (four fraction split-course SBRT): patients will undergo two fractions of SBRT durings weeks 1 and 4.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Hunter Holmes McGuire VA Medical Center</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23249</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Virginia Medical Center</Name><Address1>Charlottesville</Address1><Address2>Virginia</Address2><Address3>22908</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Virginia Commonwealth University/Massey Cancer Center</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23298</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="17870">Subjects at risk of disease recurrence</PatientSegment><SubSegments><SubSegment id="3567">Subjects with Intermediate Risk of Recurrence</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01737151</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7190">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7103"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7104">Assessment of biochemical failure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7194">Assessment of acute toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3697"><Criterion>Subjects with Specified Gleason Grade</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3699">Subjects with grade 5-7 (intermediate grade)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3702"><Criterion>Subjects with Intermediate Risk Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3719">Subjects with specified PSA levels</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4845"><Criterion>Subjects with Advanced/Metastatic Prostate Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4899">Subjects with Auto-immune/Inflammatory diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4936"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4968">Subjects on prior/concurrent radiotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4969">Subjects with prior/concurrent surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-11-09T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.77 Months</EnrollmentPeriod><EnrollmentRate>0.64 Patients/Month</EnrollmentRate><DateFirstReceived>2012-11-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-30T09:52:48Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2015-10-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-04T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>